Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network

ConclusionsCharacterization of atypicalBCR-ABL1 transcripts is essential for adequate patient monitoring and to avoid false-negative results. The results cannot be expressed on the International Scale (IS) and thus the common molecular milestones and guidelines for treatment are difficult to apply. We, therefore, suggest reporting IMR levels in these cases as a time-dependent log reduction ofBCR-ABL1 transcript levels compared to baseline prior to therapy.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research